ADJUVANT DEVELOPMENT PROGRAM - COVID-19 Supplement

Virovax Llc, Lawrence KS

Investigators

Abstract

This study will test a novel antiviral compound (kinase inhibitor) in SARS-CoV2 infected cells. This compound has been shown to inhibit flaviviruses and other CoVs (SARS and MERS).